ReviewJournal of cosmetic dermatology2026
The Role of MEF2 in Scar Formation and Angiogenesis.
Review in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyocyte enhancer factor 2 (MEF2), belonging to the Minichromosome Maintenance 1, Agamous, Deficiens and Serum Response Factor (MADS) box family with four members (MEF2A-D), plays a pivotal role in the proliferation and differentiation of various cells, including endothelial cells (ECs) and fibroblasts, as well as in physiological processes such as angiogenesis. Recent research highlights the crucial importance of MEF2 in the formation of hypertrophic scar, indicating its potential significance in scar formation and angiogenesis. However, the underlying mechanisms are still largely unexplored and warrant further investigation.
aimsThis article aims to provide a detailed summary of the connections between MEF2 and both angiogenesis and scar formation, with a focus on elucidating the possible mechanisms by which MEF2 participates in angiogenesis and scar formation.
methodsSearch on the Pubmed using the keywords MEF2, Scar, and Angiogenesis. The retrieval period spanned from January to August 2025. Summarize the viewpoints of the articles and refine the mechanisms and interconnections among MEF2, Scar, and Angiogenesis.
resultsImbalanced regulation of angiogenesis leads to abnormal scar formation. Although the role of MEF2 is not fully understood, it has been hypothesized as follows: MEF2 indirectly influences scar formation by regulating angiogenesis and vascular inflammatory responses, via the MAPK (mitogen-activated protein kinase) signaling pathway and its interplay with vascular endothelial growth factor (VEGF). On the other hand, MEF2 leads to abnormal deposition of extracellular matrix (ECM) and excessive activation of fibroblasts through its involvement in the transforming growth factor-β (TGF-β)/mothers against decapentaplegic (Smad) signaling pathway, ultimately leading to fibrosis and scar formation during the wound healing process.
conclusionsMEF2 is intimately associated with angiogenesis and scar formation. However, the mechanisms through which MEF2 is involved in these processes remain incompletely understood, necessitating further in-depth research at the genetic and molecular levels. An increasing number of studies suggest that MEF2 holds significant potential in anti-angiogenesis and scar treatment therapies, potentially emerging as a novel target for the treatment of pathological scars in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.